More Business News:
Zacks Investment Research Issues Research Update on Access Pharmaceuticals
DALLAS and NEW YORK, July 28 -- ACCESS PHARMACEUTICALS, INC. (OTC:ACCP) (BULLETIN BOARD: ACCP) , a biopharmaceutical company specializing in products for cancer and supportive care, announced today that Zacks Investment Research has issued a research update summarizing some of the recent positive developments that the Company has been able to achieve which have led to reiteration of the 'Outperform' rating on ACCP and a six-twelve month price target of $8.00.
The report can be viewed by clicking on following link:
http://www.accesspharma.com/downloads/analyst...
About Zacks:
Founded in 1978 in Chicago, Zacks Investment Research, Inc. is one of the largest independent investment research and consulting firms in the United States. With 30 years of experience, dedicated to providing clients with the highest standards of services, Zacks has become an industry leader in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.
About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.